Rovi stock: Barron's gives Rovi stock an EUR 75.85 average target

Published on 10/20/2026 at 15:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rovi reports nine-month results on November 5, 2026. Rovi stock costs EUR 58.05 on October 20, 2026, up 0.78 percent versus the BME close.

Analyst target and reporting date

Eleven ratings put the average Rovi target at EUR 75.85 on October 19, 2026.
Rovi will publish first nine months 2026 results on November 5, 2026.
Rovi stock costs EUR 58.05 at Lang & Schwarz on October 20, 2026 at 3:37 p.m. CEST, 0.78 percent above the BME close, 33.05 percent below the 52-week high.
First-half 2026 revenue growth was 13.20 percent and gross margin expanded 6.50 percentage points.

Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi (ISIN ES0157261019) has an average analyst target of EUR 75.85 from 11 ratings, according to Barron's on October 19, 2026. The target stands 30.66 percent above Rovi stock's EUR 58.05 price at Lang & Schwarz on October 20, 2026 at 3:37 p.m. CEST, up 0.78 percent versus the BME close of EUR 57.60 on October 19, 2026.

November 5 brings the next report

Rovi will publish its first nine months 2026 financial results on November 5, 2026, according to the company's investor calendar at Rovi. The date gives the market a defined checkpoint after the company's first-half 2026 report.

Stock remains near its yearly low

Rovi's 52-week range was EUR 53.10 to EUR 86.70 on October 19, 2026. At EUR 58.05, the stock stood 9.32 percent above its low and 33.05 percent below its high. The stock's year-to-date performance was minus 9.29 percent.

What does valuation show?

Rovi carried a market capitalization of EUR 2.91 billion, a trailing price-to-earnings ratio of 15.91 and a dividend yield of 1.35 percent on October 19, 2026. Its first-half 2026 report showed total revenue growth of 13.20 percent and gross margin expansion of 6.50 percentage points, according to Rovi.

Comparison with peers

Rovi: up 0.78 percent, P/E 15.91, market capitalization EUR 2.91 billion.

Almirall (BME, EUR): up 2.10 percent, P/E 30.79, market capitalization EUR 2.22 billion.

Grifols (BME, EUR): up 0.55 percent, P/E 15.17, market capitalization EUR 6.90 billion.

Price and reporting dates

The analyst target provides the clearest valuation counterpoint to Rovi's 9.32 percent cushion above its 52-week low. The next scheduled company date is November 5, 2026, when the nine-month figures will add a fresh operating reference.

Rovi stock was trading at EUR 58.05 at Lang & Schwarz on October 20, 2026 at 3:37 p.m. CEST, 0.78 percent above the BME close of October 19, 2026 at EUR 57.60. The further course of trading is shown by the continuously updated real-time quote of Rovi stock.